Renaissance IPO ETF logo

Renaissance IPO ETF (IPO)

Market Open
11 Sep, 14:01
ARCA ARCA
$
52. 38
+0.71
+1.3741%
$
193.34M Market Cap
0.03% Div Yield
18,410 Volume
$ 51.67
Previous Close
Add Transaction
Day Range
52.12 52.47
Year Range
39.31 60.33
Want to track IPO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
SpaceX Raised $86 Billion and OpenAI Is Next. This ETF Owns the IPO Class of 2026

SpaceX Raised $86 Billion and OpenAI Is Next. This ETF Owns the IPO Class of 2026

The 2026 IPO window blew open this summer. SpaceX's June listing pulled in a reported $86 billion according to Benzinga and other outlets, and Anthropic is now being floated as the next challenger to that record, with OpenAI chatter never far behind.

247wallst | 2 weeks ago
Broker pitches bullish view of "underappreciated" IP Group

Broker pitches bullish view of "underappreciated" IP Group

IP Group PLC (LSE:IPO) has seen a bullish write-up from European investment bank Berenberg, which pitches a 'Buy' rating and a 119p price target that implies around 70% upside to its current price. Berenberg describes IP Group, the investor in early-stage companies, as an “underappreciated asset” whilst noting the current 40% discount to NAV despite improving portfolio valuations and a strong liquidity position.

Proactiveinvestors | 1 month ago
IP Group board may struggle to back sweetened Railpen offer, says Deutsche Bank

IP Group board may struggle to back sweetened Railpen offer, says Deutsche Bank

The board of IP Group PLC (LSE:IPO), the London-listed technology investor, may struggle to recommend an improved takeover proposal from pension fund Railpen without further concessions, according to Deutsche Bank. Railpen returned with a revised offer ahead of today's put up or shut up deadline, when it must either make a firm bid or walk away.

Proactiveinvestors | 1 month ago
Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside

Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside

Railpen has raised its takeover proposal for IP Group PLC (LSE:IPO), offering shareholders a mix of cash, shares in Oxford Nanopore and a contingent payout linked to the biotech firm Metsera. The pension fund manager, IP Group's largest shareholder with an 18.4% stake, has made two improved proposals to the board since its initial approach on 22 June, following meetings with shareholders and directors.

Proactiveinvestors | 1 month ago
IP Group rejects Railpen takeover proposal as too low

IP Group rejects Railpen takeover proposal as too low

IP Group PLC (LSE:IPO), the company that backs spin-out businesses, has rejected a takeover proposal from one of its largest shareholders, the railways pension scheme Railpen. The board said the proposal, received on 16 June, materially undervalued the company and its prospects, and was turned down unanimously.

Proactiveinvestors | 2 months ago
Deutsche Bank unsurprised by IP Group's rejection of Railpen approach

Deutsche Bank unsurprised by IP Group's rejection of Railpen approach

Deutsche Bank has said it is 'unsurprised' that IP Group PLC (LSE:IPO) rejected a take-private approach from Railpen, its largest shareholder. The bank, whose analyst Kane Slutzkin rates the stock a 'buy' with a 110p price target, said the non-binding proposal undervalued the company on several counts.

Proactiveinvestors | 2 months ago
IP Group rejects takeover approach from its biggest shareholder

IP Group rejects takeover approach from its biggest shareholder

IP Group PLC (LSE:IPO), the London-listed investor that backs science and technology start-ups, has rejected a £616 million takeover approach from its largest shareholder. The approach came from Railpen, which manages the Railways Pension Scheme and holds 18.4% of IP Group.

Proactiveinvestors | 2 months ago
IP Group's Istesso starts phase II trial of leramistat in sarcopenia

IP Group's Istesso starts phase II trial of leramistat in sarcopenia

IP Group PLC (LSE:IPO), the FTSE 250 investment company focused on science and technology businesses, has announced that portfolio company Istesso has begun dosing patients in a phase II trial of its lead drug candidate. The study, named IST-03, is testing leramistat in patients with sarcopenia, a condition involving muscle loss, caused by rheumatoid arthritis.

Proactiveinvestors | 2 months ago
IP Group appoints former 3i chief as incoming chair

IP Group appoints former 3i chief as incoming chair

IP Group PLC (LSE:IPO), the LSE-listed science and technology investor, has appointed Michael Queen as non-executive director and chair designate, concluding a succession process announced last year. Queen will take over as chair following the company's annual general meeting on 18 June 2026, when Sir Douglas Flint retires from the board after nearly eight years of service.

Proactiveinvestors | 4 months ago
IP Group investee company First Light Fusion raises £25m in fusion energy push

IP Group investee company First Light Fusion raises £25m in fusion energy push

First Light Fusion, an IP Group PLC (LSE:IPO) portfolio company developing inertial fusion energy technology, has raised £25 million in the first close of a new funding round led by specialist fusion fund Starmaker One and backed by the UK Atomic Energy Authority (UKAEA). The round was led by East X Ventures, a UK venture firm, through its Starmaker One fusion fund, with a significant strategic investment from the UKAEA, the government body responsible for leading the UK's fusion energy programme.

Proactiveinvestors | 4 months ago
IP Group launches Australian cleantech fund with clean energy body

IP Group launches Australian cleantech fund with clean energy body

IP Group PLC (LSE:IPO), the LSE-listed science and technology investor, has launched a new fund with Australia's Clean Energy Finance Corporation (CEFC) to back cleantech companies targeting hard-to-abate industries. The IP Group Climate Catalyst Fund has a target size of up to A$150 million, with IP Group contributing A$30 million and the CEFC A$20 million as cornerstone investors at first close.

Proactiveinvestors | 5 months ago
Here's why IP Group looks undervalued. Three brokers take a deep dive

Here's why IP Group looks undervalued. Three brokers take a deep dive

Analysts at three brokerages maintain 'buy' ratings after strong full-year results IP Group PLC (LSE:IPO), the London-listed investor that commercialises intellectual property from leading universities, reported a 13% rise in net asset value (NAV) per share to 110.4p for the year ended December 2025, driven by a licensing deal tied to Pfizer's $10 billion acquisition of obesity drug developer Metsera. The company's shares rose 11% on Tuesday to 54.7p.

Proactiveinvestors | 5 months ago
Loading...
Load More